Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,288 papers from all fields of science
Search
Sign In
Create Free Account
Dipeptidyl Peptidase-4 Inhibitor
Known as:
DPP-4 Inhibitor
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Dipeptidyl Peptidase 4 Inhibitor [EPC]
Dipeptidyl Peptidase 4 Inhibitors [MoA]
Dipeptidyl-Peptidase IV Inhibitors
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
M. J. Kim
,
N. Kim
,
+7 authors
K. Park
Diabetes & Metabolism Journal
2019
Corpus ID: 207945690
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors…
Expand
Review
2018
Review
2018
Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes
Ben Wang
,
Yan Sun
,
Y. Sang
,
Xuekui Liu
,
Jun Liang
Medicine
2018
Corpus ID: 53442113
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with…
Expand
2016
2016
Cardiovascular safety of glucose‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
Nils Ekström
,
A. Svensson
,
+4 authors
S. Gudbjörnsdottir
Diabetes, obesity and metabolism
2016
Corpus ID: 42745450
To investigate the relative safety of various glucose‐lowering agents as add‐on medication to metformin in type 2 diabetes in an…
Expand
2015
2015
The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
Salheen M. Salheen
,
U. Panchapakesan
,
C. Pollock
,
O. Woodman
Pharmacological Research
2015
Corpus ID: 24653785
2013
2013
Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
S. Furuta
,
M. Tamura
,
H. Hirooka
,
Yukie Mizuno
,
M. Miyoshi
,
Y. Furuta
European journal of drug metabolism and…
2013
Corpus ID: 12812528
The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was…
Expand
2013
2013
The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice
Yu-peng Li
,
Jing Xiao
,
+8 authors
Hua Shu
Peptides
2013
Corpus ID: 45044450
Highly Cited
2011
Highly Cited
2011
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, and pioglitazone on glycemic control and measures of β‐cell function in patients with type 2 diabetes
K. Yoon
,
G. Shockey
,
+7 authors
H. Steinberg
International journal of clinical practice
2011
Corpus ID: 27413088
Aim/hypothesis: To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with…
Expand
2010
2010
Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in…
S. Retlich
,
V. Duval
,
+6 authors
U. Graefe‐Mody
Clinical Pharmacokinetics
2010
Corpus ID: 29540247
Background and ObjectivesLinagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently…
Expand
Highly Cited
2009
Highly Cited
2009
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
E. U. Graefe-Mody
,
S. Padula
,
A. Ring
,
B. Withopf
,
Klaus A. Dugi
Current Medical Research and Opinion
2009
Corpus ID: 12081741
ABSTRACT Objective: Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin…
Expand
Review
2009
Review
2009
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
A. Tiwari
Current opinion in investigational drugs
2009
Corpus ID: 46370241
Boehringer Ingelheim Corp is developing the novel, xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor linagliptin for the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE